MetLife Investment Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.93M | Buy |
48,212
+5,334
| +12% | +$385K | 0.02% | 775 |
|
|
2026
Q1 | $2.92M | Sell |
42,878
-676
| -2% | -$47.9K | 0.01% | 863 |
|
|
2025
Q4 | $3.31M | Sell |
43,554
-1,737
| -4% | -$126K | 0.02% | 815 |
|
|
2025
Q3 | $2.78M | Sell |
45,291
-1,040
| -2% | -$54.2K | 0.01% | 930 |
|
|
2025
Q2 | $2.26M | Buy |
46,331
+1,977
| +4% | +$93.9K | 0.01% | 938 |
|
|
2025
Q1 | $2.26M | Sell |
44,354
-2,234
| -5% | -$111K | 0.01% | 985 |
|
|
2024
Q4 | $2.1M | Buy |
46,588
+2,581
| +6% | +$110K | 0.01% | 1008 |
|
|
2024
Q3 | $1.63M | Hold |
44,007
| – | – | 0.01% | 1133 |
|
|
2024
Q2 | $1.35M | Buy |
44,007
+6,827
| +18% | +$221K | 0.01% | 1185 |
|
|
2024
Q1 | $1.08M | Hold |
37,180
| – | – | 0.01% | 1253 |
|
|
2023
Q4 | $1.02M | Hold |
37,180
| – | – | 0.01% | 1277 |
|
|
2023
Q3 | $833K | Hold |
37,180
| – | – | 0.01% | 1341 |
|
|
2023
Q2 | $1.51M | Hold |
37,180
| – | – | 0.01% | 1052 |
|
|
2023
Q1 | $1.8M | Hold |
37,180
| – | – | 0.01% | 956 |
|
|
2022
Q4 | $1.42M | Hold |
37,180
| – | – | 0.01% | 1036 |
|
|
2022
Q3 | $1.87M | Buy |
37,180
+276
| +0.7% | +$13.5K | 0.02% | 909 |
|
|
2022
Q2 | $1.48M | Sell |
36,904
-1,535
| -4% | -$53.8K | 0.01% | 1026 |
|
|
2022
Q1 | $1.43M | Buy |
38,439
+13,448
| +54% | +$518K | 0.01% | 1135 |
|
|
2021
Q4 | $995K | Hold |
24,991
| – | – | 0.01% | 1125 |
|
|
2021
Q3 | $930K | Hold |
24,991
| – | – | 0.01% | 1150 |
|
|
2021
Q2 | $1.06M | Buy |
24,991
+1,477
| +6% | +$63.3K | 0.01% | 1133 |
|
|
2021
Q1 | $1.11M | Sell |
23,514
-2,054
| -8% | -$122K | 0.01% | 1106 |
|
|
2020
Q4 | $1.56M | Sell |
25,568
-1,698
| -6% | -$100K | 0.01% | 935 |
|
|
2020
Q3 | $1.27M | Hold |
27,266
| – | – | 0.01% | 922 |
|
|
2020
Q2 | $1.38M | Buy |
27,266
+1,474
| +6% | +$72.4K | 0.02% | 891 |
|
|
2020
Q1 | $1.15M | Hold |
25,792
| – | – | 0.02% | 840 |
|
|
2019
Q4 | $1.24M | Hold |
25,792
| – | – | 0.01% | 985 |
|
|
2019
Q3 | $872K | Hold |
25,792
| – | – | 0.01% | 1138 |
|
|
2019
Q2 | $1.16M | Sell |
25,792
-42,839
| -62% | -$1.69M | 0.01% | 1043 |
|
|
2019
Q1 | $2.58M | Buy |
68,631
+47,581
| +226% | +$1.6M | 0.01% | 1122 |
|
|
2018
Q4 | $722K | Hold |
21,050
| – | – | 0.01% | 1160 |
|
|
2018
Q3 | $989K | Hold |
21,050
| – | – | 0.01% | 1126 |
|
|
2018
Q2 | $710K | Buy |
21,050
+1,850
| +10% | +$57.7K | 0.01% | 1191 |
|
|
2018
Q1 | $520K | Hold |
19,200
| – | – | 0.01% | 1341 |
|
|
2017
Q4 | $320K | Buy |
+19,200
| New | +$325K | ﹤0.01% | 1673 |
|
Other funds holding PTCT
RI
JT
MetLife Investment Management's PTCT Position: Q2 2026 in Review
MetLife Investment Management increased its PTC Therapeutics (PTCT) stake by 12% in Q2 2026, buying an estimated $385K and bringing the position to 48,212 shares worth $3.93M. The position accounts for 0.02% of the portfolio, ranked #775.
MetLife Investment Management first reported a position in PTCT in Q4 2017 and has held it in 35 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- MetLife Investment Management held 48,212 shares of PTC Therapeutics worth $3.93M as of Q2 2026.
- MetLife Investment Management bought 5,334 PTC Therapeutics shares in Q2 2026, an estimated $385K.
- PTC Therapeutics made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #775 holding.
- MetLife Investment Management first reported a position in PTC Therapeutics in Q4 2017 and has held it in 35 quarters since.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.